Chapter title |
Disrupting Tumor Angiogenesis and “the Hunger Games” for Breast Cancer
|
---|---|
Chapter number | 8 |
Book title |
Translational Research in Breast Cancer
|
Published in |
Advances in experimental medicine and biology, January 2017
|
DOI | 10.1007/978-981-10-6020-5_8 |
Pubmed ID | |
Book ISBNs |
978-9-81-106019-9, 978-9-81-106020-5
|
Authors |
Ziwei Zhou, Herui Yao, Hai Hu |
Abstract |
Angiogenesis, one of the hallmarks of cancers, has become an attractive target for cancer therapy since decades ago. It is broadly thought that upregulation of angiogenesis is involved in tumor progression and metastasis. Though tumor vessels are tortuous, disorganized, and leaky, they deliver oxygen and nutrients for tumor development. Based on this knowledge, many kinds of drugs targeting angiogenesis pathways have been developed, such as bevacizumab. However, the clinical outcomes of anti-angiogenesis therapies are moderate in metastatic breast cancer as well as in metastatic colorectal cancer and non-small cell lung cancer, even combined with traditional chemotherapy. In this chapter, the morphologic angiogenesis patterns and the key molecular pathways regulating angiogenesis are elaborated. The FDA-approved anti-angiogenesis drugs and current challenges of anti-angiogenesis therapy are described. The strategies to overcome the barriers will also be elucidated. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 21 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 4 | 19% |
Student > Master | 2 | 10% |
Researcher | 2 | 10% |
Student > Ph. D. Student | 2 | 10% |
Other | 1 | 5% |
Other | 3 | 14% |
Unknown | 7 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 24% |
Agricultural and Biological Sciences | 4 | 19% |
Biochemistry, Genetics and Molecular Biology | 2 | 10% |
Immunology and Microbiology | 1 | 5% |
Social Sciences | 1 | 5% |
Other | 1 | 5% |
Unknown | 7 | 33% |